BioStock: Iconovo’s partner explores opportunities in Bangladesh

Together with ISR, Iconovo is developing an inhaled Covid-19 vaccine in ICOone and a nasal version in ICOone Nasal. ISR has now signed a MoU agreement with the CRO Bangladesh Clinical Trials for a clinical phase I study with the vaccine, as well as with UniMed UniHealth Pharmaceuticals for manufacturing and distribution in Bangladesh. However, these agreements are only declarations of intent, not binding agreements, but they are nevertheless good news for Iconovo as it means significant progress within the vaccine project.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/08/iconovos-partner-explores-opportunities-in-bangladesh/
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se